Seres Therapeutics Enacts 1-for-10 Reverse Stock Split

TL;DR

**Seres Therapeutics just did a 1-for-10 reverse stock split to pump up its share price.**

AI Summary

Seres Therapeutics, Inc. (MCRB) filed an 8-K on January 2, 2024, to report an amendment to its Certificate of Incorporation. This amendment, approved by stockholders on December 28, 2023, and effective January 2, 2024, implements a 1-for-10 reverse stock split of its common stock. This action is crucial for investors as it aims to increase the per-share trading price, potentially to maintain its listing on The Nasdaq Stock Market LLC, which often has minimum bid price requirements.

Why It Matters

This reverse stock split aims to boost Seres Therapeutics' stock price, which is critical for maintaining its Nasdaq listing and potentially attracting institutional investors. It could signal a move to improve the company's financial perception.

Risk Assessment

Risk Level: medium — Reverse stock splits often indicate a company is struggling to maintain its stock price and can sometimes be followed by further price declines, though it can also be a necessary step for compliance.

Analyst Insight

Investors should monitor MCRB's stock performance post-split to see if the higher share price is sustained and if the company addresses underlying issues that led to the need for a reverse split. Evaluate the company's fundamentals and future prospects, as reverse splits can sometimes be a precursor to further challenges.

Key Numbers

• 1-for-10 — reverse stock split ratio (each 10 shares of common stock will be converted into 1 share)
• January 2, 2024 — effective date of reverse stock split (the date the reverse stock split became effective)
• December 28, 2023 — stockholder approval date (the date stockholders approved the reverse stock split)

Key Players & Entities

• Seres Therapeutics, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where Seres Therapeutics' common stock is registered
• MCRB (company) — the trading symbol for Seres Therapeutics

Forward-Looking Statements

• Seres Therapeutics will maintain its Nasdaq listing due to the increased share price. (Seres Therapeutics, Inc.) — medium confidence, target: Q2 2024
• The stock price per share will initially increase proportionally to the split ratio. (MCRB) — high confidence, target: January 2024

FAQ

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar

Filing Documents

• d582286d8k.htm (8-K) — 31KB
• d582286dex31.htm (EX-3.1) — 187KB
• 0001193125-24-000683.txt ( ) — 377KB
• mcrb-20240102.xsd (EX-101.SCH) — 3KB
• mcrb-20240102_lab.xml (EX-101.LAB) — 18KB
• mcrb-20240102_pre.xml (EX-101.PRE) — 11KB
• d582286d8k_htm.xml (XML) — 3KB

03

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On January 2, 2024, the Board of Directors (the " Board ") of Seres Therapeutics, Inc., a Delaware corporation (the " Company ") approved and adopted the Company's Amended and Restated Bylaws (the " Amended and Restated Bylaws "), which became effective the same day. Among other things, the amendments contained in the Amended and Restated Bylaws: Address the universal proxy rules adopted by the U.S. Securities and Exchange Commission, by providing that no person may solicit proxies in support of a director nominee other than the Board's nominees unless such person has, or is part of a group that has, complied with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the " Exchange Act "), including applicable notice and solicitation requirements. Update disclosure requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at stockholder meetings (other than proposals to be included in the Company's proxy materials pursuant to Rule 14a-8 under the Exchange Act), including, without limitation, disclosure of derivative security interests and material interests, agreements and relationships between a proposing stockholder (and other participants in a solicitation) and the Company as well as between proposed director nominees and a proposing stockholder and providing that the Board may request a proposing stockholder or proposed director nominee to provide additional information as reasonably required by the Board. Prohibit the submission by a proposing stockholder of more director nominees than the number of directors up for election. Require that a stockholder directly or indirectly soliciting proxies from other stockholders use a proxy card color other than white. Clarify personal jurisdiction and service of process matters for foreign actions within the scope of the Company's forum selection pr

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Amended and Restated Bylaws of Seres Therapeutics, Inc. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 2, 2024 SERES THERAPEUTICS, INC. By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Chief Legal Officer and Executive Vice President

View Full Filing

View this 8-K filing on SEC EDGAR